CPA
MDGL icon

Capital Performance Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Capital Performance Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,422
Closed -$802K – 300
2025
Q1 		$802K Buy
+2,422
New +$796K 0.18% 68
2024
Q4 		– Sell
-3
Closed -$637 – 1637
2024
Q3 		$637 Buy
+3
New +$767 ﹤0.01% 2137

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital Performance Advisors's MDGL Position: Q2 2025 in Review

Capital Performance Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 2,422 shares — an estimated $802K sold.

Capital Performance Advisors first reported a position in MDGL in Q3 2024 and held it in 2 quarters. The position peaked at $802K in Q1 2025. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Capital Performance Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capital Performance Advisors sold 2,422 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $802K.
  • Capital Performance Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Capital Performance Advisors's Madrigal Pharmaceuticals position peaked at $802K in Q1 2025.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Capital Performance Advisors's 13F filing for Q2 2025, filed 4 Aug 2025.